萬替妥單抗
化合物
萬替妥單抗（INN：Vantictumab）是一種人IgG2單株抗體，設計用於治療癌症。[1]
| 單株抗體 | |
|---|---|
| 種類 | ? |
| 目標 | 捲曲受體 |
| 臨床資料 | |
| 給藥途徑 | IV |
| ATC碼 |
|
| 識別資訊 | |
| CAS號 | 1345009-45-1 |
| ChemSpider |
|
| UNII | |
| KEGG | |
| 化學資訊 | |
| 化學式 | C6322H9722N1674O1988S46 |
| 摩爾質量 | 142,461.81 g·mol−1 |
該藥物由OncoMed製藥公司與拜耳合作開發。[2]OncoMed於2016年獲得專利，預計將於2029年到期。[3]2017年4月，拜耳終止了對萬替妥單抗的許可選擇。[4]
胰腺癌、非小細胞肺癌和乳腺癌的I期試驗已經完成。2016年報告了三陰性乳腺癌1b期臨床試驗的結果，[5][6]2020年報告了胰腺癌的1b期臨床試驗結果。[7]
參考資料
- ^ Statement on a nonproprietary name adopted by the USAN Council (PDF). AMA. 28 Nov 2012. N12/155.
- ^ OncoMed Pre-Announces 2014 Year-End Cash Balance and Provides 2015 Guidance. 12 January 2015 [2024-03-01]. （原始內容存檔於2024-03-01）.
- ^ Annual Report on Form 10-K. OncoMed Pharmaceuticals, Inc. （原始內容存檔於13 January 2017）.
- ^ BRIEF-Oncomed Pharmaceuticals announces Bayer terminates its option to license vantictumab or ipafricept. Reuters. 10 April 2017 [2024-03-01]. （原始內容存檔於2021-05-18）.
- ^ 5.0 5.1 Finally, targeted therapies for triple-negative breast cancer. Medical Xpress. June 2016 [2024-03-01]. （原始內容存檔於2024-01-08）.
- ^ Diamond JR, Becerra C, Richards D, Mita A, Osborne C, O'Shaughnessy J, et al. Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer. Breast Cancer Research and Treatment. November 2020, 184 (1): 53–62. PMC 7572714
. PMID 32803633. doi:10.1007/s10549-020-05817-w.
- ^ Davis SL, Cardin DB, Shahda S, Lenz HJ, Dotan E, O'Neil BH, et al. A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer. Investigational New Drugs. June 2020, 38 (3): 821–830. PMC 7211194 . PMID 31338636. doi:10.1007/s10637-019-00824-1.
 | 這是一篇與藥學相關的小作品。您可以透過編輯或修訂擴充其內容。 |